Clovis takes stock as rival Tesaro shines
Oncology firm could make acquisition if ovarian cancer drug approved.
Oncology firm could make acquisition if ovarian cancer drug approved.
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Despite Keytruda’s overwhelming victory, it’s not over yet in NSCLC
But BMS dumps combination with Yervoy.
Merck unveils impressive data on Keytruda, trumping BMS’ Opdivo
Commentary on key cancer data from ESMO by Stephanie Hawthorne
Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
Europe’s biggest cancer conference ESMO is underway